A global biotechnology company headquartered near Cologne in Bergisch Gladbach, Germany. The company is a provider of products and services that support scientists, clinical researchers, and physicians across basic research, translational research, and clinical applications. The company offers solutions covering techniques of sample preparation, cell separation, cell sorting, flow cytometry, cell culture, molecular analysis, clinical applications and small animal imaging.
A knowledge-based company, established in May 1999 in Italy, primarily involved in the development, production and commercialization of electromedical systems based on extracorporeal circulation technologies.
Was formed In December 2009 by Patrizia Paterlini Brechot, Professor of Cell Biology and Oncology, in order to commercialize the result of her research: the patented ISET (Isolation by Size of Epithelial/Throphoblastic Tumor cells) device to isolate Circulating Rare Cells in blood.
A newly established brand which is expected to set a new standard in the field of cell culture. We specialize in the manufacture and worldwide distribution of cell culture products for research, development, diagnostic and biopharmaceutical production. The company manufactures products for the cultivation, storage and separation of cells.
A Japanese international chemical manufacturing companybased in Osaka and founded in 1949. The company produces chemical products such as functional resin, foam resin, andsynthetic fibers. The company was also engaged in the medical equipment business. In recent years, the company manufactured raw material for production of coenzyme Q10, and apheresis devices, where blood of a donor or patient is passed through an apparatus that separates out one particular constituent and returns the remainder to the circulation.
Jafron Biomedical Co., Ltd. was established in 1989. It is mainly engaged in RD, production and marketing of biomaterials & medical devices. It is not only a leading enterprise in China blood purification industry but also the first public company listed its A-share on the GEM which was growing and developing from the field of blood purification, whose mainly business was blood purification products. Jafron has won China 2009 National 2nd Prize for Progress in Science & Technology, listed in Forbes of China Potential Enterprises in 2010 & 2011 successively. It was identified as "China National Torch Program key High-tech Enterprise" in 2011. The company has passed CE Certification, ISO International Quality Certification & China GMP National Certification. It undertakes two China National Key & New Product Projects and three China National Torch Plan Projects. It is authorized by the government to set up Guangdong Engineering Research Center (ERC). It is of great capability of RD, production & national sales network and the products have reached international advanced level. Its major products of DNA Immunoadsorption Column & HA Resin Hemoperfusion Cartridge have stable leading market shares in blood purification industry.
In 2015, a world-class modern blood purification RD & manufacturing base, Jafron Tech Park, in the head office city of Zhuhai, was successfully completed and went into operation. In 2020, Jafron will develop into a professional provider of comprehensive solutions for blood purification, and expand other fields of biomedicine in a timely manner, laying a solid foundation for realizing the enterprise vision of becoming “a world’s leading high-tech medical technology enterprise group”.